Doxorubicin-Mediated Bone Loss in Breast Cancer Bone Metastases Is Driven by an Interplay between Oxidative Stress and Induction of TGFβ

Breast cancer patients, who are already at increased risk of developing bone metastases and osteolytic bone damage, are often treated with doxorubicin. Unfortunately, doxorubicin has been reported to induce damage to bone. Moreover, we have previously reported that doxorubicin treatment increases ci...

Descripción completa

Detalles Bibliográficos
Autores principales: Rana, Tapasi, Chakrabarti, Anwesa, Freeman, Michael, Biswas, Swati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813496/
https://www.ncbi.nlm.nih.gov/pubmed/24205081
http://dx.doi.org/10.1371/journal.pone.0078043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813496/
https://www.ncbi.nlm.nih.gov/pubmed/24205081
http://dx.doi.org/10.1371/journal.pone.0078043

Ejemplares similares